Genetically modified T cell therapies have been in the news for their ability to improve outcomes for cancer patients, especially those with blood cancers. A recent longitudinal study followed nearly 800 patients treated with T cell therapies across 38 clinical trials to collate safety data, discovering that serious complications, especially T cell malignancies, were extremely rare. Demonstrating the safety of this treatment modality is a first step in discovering whether genetically modified T cell therapy might be a treatment for patients with less immediately deadly diseases. Researchers believe that this treatment modality may hold promise for targeting fibrosis in the future. Discover how Myhre Syndrome Foundation is looking at T cell therapy in our Research Roadmap.

Read the full article on The Scientist.